Physicians' Academy for Cardiovascular Education

Triglycerides

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins

3' education - May 24, 2022 - Nicholas Marston, MD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

MI risk is best captured by number of apoB-containing lipoproteins

5' education - Apr. 20, 2022 - Nicolas Marston, MD

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD

Targeting triglyceride-rich remnant lipoproteins

10' education - Dec. 21, 2021 - Prof. Daniel Gaudet, MD, PhD

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD
Prof. Sattar shares his thoughts on why high triglycerides reflect ectopic fat and how this relationship may help to motivate patients to sustain weight improvements and lower CV and diabetes risks.

Prof. Sattar shares his thoughts on why high triglycerides reflect ectopic fat and how this relationship may help to motivate patients to sustain weight improvements and lower CV and diabetes risks.

Final guidance by NICE in UK on recommendation for use of icosapent ethyl

News - July 19, 2022

NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.

CAC score can identify REDUCE-IT-eligible patients who benefit most from icosapent ethyl

Literature - July 18, 2022 - Mortensen MB, et al. - Eur J Prev Cardiol. 2022

The REDUCE-IT trial showed that treatment with icosapent ethyl is effective in patients receiving a statin who meet certain biochemical criteria. The CAC score may help to identify patients who would benefit most from this treatment.

NICE publishes final draft guidance on icosapent ethyl

News - June 13, 2022

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.

First results with a monoclonal antibody against ANGPTL3/8 complex

News - May 24, 2022

EAS 2022 The ANGPLT3/8 complex inhibits LPL 100-fold more potently than ANGPLT3 alone, making this complex an attractive target for CVD prevention in subjects with mixed hyperlipidemia.

Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins

3' education - May 24, 2022 - Nicholas Marston, MD
An ASO targeting //ANGPTL3// mRNA, significantly reduced VLDL and remnant cholesterol, but had side effects at higher doses. What could be next steps in this research area?

EAS 2022 An ASO targeting ANGPTL3 mRNA, significantly reduced VLDL and remnant cholesterol, but had side effects at higher doses. What could be next steps in this research area?

E-learning CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!

Childhood risk factors associated with CV events in adulthood

Literature - Apr. 26, 2022 - Jacobs, Jr. DE et al. - N Engl J Med. 2022

A study demonstrated that traditional CV factors (BMI, SBP, total cholesterol level, triglyceride level, and smoking) in childhood are associated with CV events during adulthood.

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

MI risk is best captured by number of apoB-containing lipoproteins

5' education - Apr. 20, 2022 - Nicolas Marston, MD
Does the type or lipid content of apoB-containing lipoprotein carry any additional risk of MI beyond the total number of apoB-containing lipoproteins?

Does the type or lipid content of apoB-containing lipoprotein carry any additional risk of MI beyond the total number of apoB-containing lipoproteins?

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in  patients who are already being treated with statins.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.